However, when women used steroid-resembling estrogen drugs in MHT, the risk of ovarian cancer was carefully evaluated because synthesized estrogen analogues possibly bind to ERα and ERβ unequally (32,33). This evidence concerns the gene ESR2 and ovarian cancer.